The 20 Best Renal Cell Carcinoma (RCC) Doctors Near Me

Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). She is also highly rated in 13 other conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). Dr. Brahmer is board certified in American Board Of Internal Medicine.

Dr. Noah Hahn is a medical oncologist in the Baltimore area, caring for patients with bladder cancer. He serves as the deputy director of the Greenberg Bladder Cancer Institute at the Johns Hopkins School of Medicine. Dr. Hahn earned his M.D. from Indiana University School of Medicine. He completed his residency in internal medicine at Duke University School of Medicine and performed a fellowship in medical oncology at Indiana University School of Medicine. Dr. Hahn joined the Johns Hopkins faculty in 2014. Prior to joining Johns Hopkins, Dr. Hahn was the director of the Genitourinary Medical Oncology Program at Indiana University and chief scientific officer for the Hoosier Oncology Group, a cancer research organization that evaluates innovative and promising approaches to cancer treatment. He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer. Dr. Hahn is a member of the Bladder Cancer Task Force for the National Cancer Institute’s Genitourinary Cancer Steering Committee and is chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group. Dr. Hahn is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy.

I specialize in the care of patients with urologic cancers – mainly prostate cancer, kidney cancer, bladder cancer and testicular cancer. A cancer diagnosis is one of the scariest things that can happen to someone. For many of our patients, they don’t necessarily feel different or look different, but they are scared to death. The most important thing you can get from Duke is real understanding of your particular case and what your options are. Knowledge is so reassuring and empowering for patients, especially those recently diagnosed with cancer. When you’re first diagnosed, you have to put your trust in a care team, and that’s hard to do if you don’t already know them. As the largest cancer center in North Carolina, Duke has great reputation and experience, which helps many patients chose Duke for their care. But we grow and develop our trust with patients because of who we are as people and how much expertise and care we bring to each case. Dr. George is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Nephrectomy, and Orchiectomy.

Joshua Meeks is an Oncologist practicing medicine in Chicago, Illinois. He has been practicing medicine for over 21 years. Dr. Meeks is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 20 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Orchiectomy, and Reconstructive Urology Surgery. Dr. Meeks is board certified in American Board Of Urology - Urology (Certified).

Melissa Burgess, MD, is an assistant professor at the University of Pittsburgh School of Medicine and a medical oncologist. She specializes in the treatment of soft tissue and bone sarcomas and Merkel cell carcinoma. Dr. Burgess is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). She is also highly rated in 42 other conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Merkel Cell Carcinoma, Chondrosarcoma, and Gamma Knife Radiosurgery. Dr. Burgess is board certified in American Board Of Internal Medicine. Dr. Burgess is currently accepting new patients.

Mehmet Bilen is an Oncologist practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 18 years. Dr. Bilen is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Prostate Cancer, Urothelial Cancer, Nephrectomy, and Tissue Biopsy. Dr. Bilen is board certified in American Board Of Internal Medicine, 2016.

Seth P. Lerner, MD, is Professor of Urology and holds the Beth and Dave Swalm Chair in Urologic Oncology, in the Scott Department of Urology, Baylor College of Medicine. He is Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program and Faculty Group Practice Medical Director for the Urology Clinic. He earned his medical degree from Baylor College of Medicine, completed a surgical internship at Virginia Mason Hospital in Seattle, and returned to Baylor for his residency training. He completed a two-year fellowship at the University of Southern California in urologic oncology and reconstructive surgery under Peter Jones and Don Skinner before returning to join the full-time Baylor faculty in 1992. His clinical practice, education, and research activities are devoted to urologic oncology and particularly lower and upper tract urothelial cancer. Dr. Lerner is author of more than 160 peer-reviewed articles, and co-editor of a comprehensive Textbook of Bladder Cancer. Dr. Lerner is an active member of the prestigious American Association of Genitourinary surgeons and is listed routinely among America's Top Doctors and Best Doctors in America. He established and directs the multi-disciplinary Bladder Cancer Research Program at Baylor, and his research interests include use of selective estrogen receptor modulators for treatment of bladder cancer, gene therapy, targeted molecular therapeutics, and outcomes of radical cystectomy and pelvic lymphadenectomy. He has 22 years of experience as a clinical investigator for both NCI and industry funded clinical trials. He is the PI of the ongoing SWOG NCI Phase III trial comparing extended vs. standard pelvic lymphadenectomy at time of radical cystectomy for muscle invasive bladder cancer. He is active in the leadership of several national bladder cancer research enterprises including chair of the Local Bladder Cancer committee of SWOG, co-chair of the NCI's Bladder Cancer Task Force and the Analysis Working Group of The Cancer Genome Atlas Project for muscle invasive bladder cancer. He is very active in the Bladder Cancer Advocacy Network (BCAN) as a member of the Board of Directors, past chair of the Bladder Cancer Think Tank and co-chair of the management committee of the Bladder Cancer Research Network. Dr. Lerner is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy. Dr. Lerner is currently accepting new patients.

Moshe Ornstein is an Oncologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 21 years. Dr. Ornstein is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Gamma Knife Radiosurgery. Dr. Ornstein is board certified in American Board Of Internal Medicine, 2017.

David Mcdermott is an Internal Medicine specialist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Mcdermott is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Melanoma, Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, and Nephrectomy. Dr. Mcdermott is board certified in American Board Of Internal Medicine.

Kevin Kalinsky is an Oncologist practicing medicine in Atlanta, Georgia. Dr. Kalinsky is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, HER2 Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Inflammatory Breast Cancer.

Richard Carvajal is an Oncologist practicing medicine in Lake Success, New York. Dr. Carvajal is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Metastatic Uveal Melanoma, Uveal Melanoma, Melanoma of the Eye, Melanoma, and Tissue Biopsy. Dr. Carvajal is board certified in American Board Of Internal Medicine/Medical Oncology.

Dr. Jean Hoffman-Censits is a genitourinary cancer specialist in Baltimore, caring for patients with urothelial cancers of the bladder and upper tract. She serves as co-leader of the Women’s Bladder Cancer Program in the Greenberg Bladder Cancer Institute at the Johns Hopkins University School of Medicine. Dr. Hoffman-Censits received her undergraduate degree in neuroscience from Trinity College. She earned her M.D. degree from the Sidney Kimmel Medical College of Thomas Jefferson University. She completed her residency at Thomas Jefferson University Hospital and performed a fellowship in hematology and oncology at Temple University Medical Center. She joined the Johns Hopkins faculty in 2018. Dr. Hoffman-Censits's research interests focus on urothelial cancers. Her clinical research has helped identify urothelial cancer sub-types and establish new treatments for bladder and upper tract urothelial cancers. She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Urological Association and the Society for Immunotherapy of Cancer. Dr. Hoffman is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Bladder Reconstruction, and Nephrectomy. Dr. Hoffman is board certified in American Board Of Internal Medicine.

Bradley Carthon is an Oncologist practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 21 years. Dr. Carthon is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Prostatectomy. Dr. Carthon is board certified in American Board Of Internal Medicine, 2011.

Scott Antonia is an Oncologist practicing medicine in Durham, North Carolina. He has been practicing medicine for over 37 years. Dr. Antonia is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma. Dr. Antonia is board certified in American Board Of Internal Med, Medical Oncology.

Jacob Sands is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Sands is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma. Dr. Sands is board certified in Medical Oncology.

Roger Cohen is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Cohen is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 31 other conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Tissue Biopsy, and Endoscopy. Dr. Cohen is board certified in Medical Oncology, 1993, Hematology, 1986, and Internal Medicine, 1984. Dr. Cohen is currently accepting new patients.

Shilpa Gupta is an Oncologist practicing medicine in Cleveland, Ohio. Dr. Gupta is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). She is also highly rated in 17 other conditions, according to our data. Her clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Gamma Knife Radiosurgery.

Francesco Montorsi practices practicing medicine in Milan, Italy. Mr. Montorsi is rated as an Elite expert by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 56 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Bladder Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Cystectomy.

Alberto Briganti practices practicing medicine in Milan, Italy. Mr. Briganti is rated as an Elite expert by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 38 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Bladder Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Cystectomy.

Naval Daver is an Oncologist practicing medicine in Houston, Texas. Dr. Daver is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). He is also highly rated in 39 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.